Aβ42-IN-2

CAS No. 1914989-80-2

Aβ42-IN-2( —— )

Catalog No. M37643 CAS No. 1914989-80-2

Aβ42-IN-2, a γ-secretase modulator with an IC50 of 6.5 nM for Αβ42, can be used for Alzheimer's disease research .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 89 In Stock
5MG 82 In Stock
10MG 129 In Stock
25MG 215 In Stock
50MG 299 In Stock
100MG 412 In Stock
200MG 570 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Aβ42-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    Aβ42-IN-2, a γ-secretase modulator with an IC50 of 6.5 nM for Αβ42, can be used for Alzheimer's disease research .
  • Description
    Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC50 of 6.5 nM for Αβ42.Aβ42-IN-2 can be used for the research of Alzheimer's disease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    Gamma-secretase
  • Recptor
    Gamma-secretase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1914989-80-2
  • Formula Weight
    430.5
  • Molecular Formula
    C24H26N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 20 mg/mL (46.46 mM; Ultrasonic )
  • SMILES
    COc1ccc(cc1)[C@H](C)Nc1nnc(cc1C)-c1ccc(c(OC)n1)-n1cnc(C)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Steven L. Wagner, et al. Potent gamma-secretase modulators. WO2016070107A1.
molnova catalog
related products
  • PEAQX

    PEAQX(NVP-AAM 077) is an effective and orally available NMDA antagonist. It can inhibit human NMDA receptors for 1A/2A(IC50: 270 nM), rather than 1A/2B(29, 600 nM).

  • Enoticumab

    Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.

  • 5β-Cholanic acid

    5β-Cholanic acid (5beta-Cholanic acid) is a potent γ-secretase modulator used in Alzheimer's disease research.